Stallen Overview-Indian Animal Health Industry
The veterinary healthcare sector in India is experiencing significant growth, with the market size estimated to be USD 1.25 billion in 2024, projected to reach USD 1.89 billion by 2029, indicating a robust CAGR of 8.63% during the forecast period. This growth is particularly notable in the poultry industry, which has emerged as one of the fastest-growing sectors among livestock species. The poultry sector has evolved into a key supplier of affordable protein sources, driving the development of value chains that cater to consumer demand.
Stallen South Asia: Leading by Change and Setting a Standard
In response to this market dynamic, Stallen South Asia Private Limited has emerged as a key player, offering indigenous solutions and expertise in animal health. By bridging the gap between global standards and local requirements, companies like Stallen are not only contributing to the growth of the poultry industry but also fostering a resilient and sustainable ecosystem for animal health management in the country.
Stallen stands out as a leading name in India’s animal health sector, offering a diverse range of products tailored for poultry and cattle across four distinct divisions. These divisions encompass feed additives, biosecurity solutions, formulations, and vaccines, showcasing Stallen’s comprehensive approach to animal health management.
Stallen’s new Therapeutic Facility
Strategic Collaborations and Industry Partnerships – 25 Years in the Marking
The company’s journey traces back to its inception in 1997. Since inception, Stallen has constantly developed to stay in line with the industry standard – in 2010 Stallen entered a JV with FATRO from Bologna, Italy. This JV enabled Stallen to import and distribute a wide range of killed and live vaccines, further solidifying its position in the market.
Dedicated Storage at the Palghar Facility
Global Reach and Market Presence
Over the 25 years, Stallen has expanded its footprint and capacities. Today, Stallen’s export operations span more than 50 countries across 6 continents serving as a testament to our product quality and service.
In an attempt to completely self suffienct, Stallen has backward integrated and control the end-to-end supply chain. As a result, they currently operate 5 different manufacturing locations in addition to the 2 supply plants of FATRO:
1) Feed Additives Manufacturing Unit in Palghar, Maharashtra
2) Feed Additives Manufacturing Unit in Sajjanpada, Maharashtra
3) Feed Additives and Cattle Feed Premix Manufacturing Unit in Alexandria, Canada
4) Therapeutics/Formulations Manufacturing Unit in Nandore, Maharashtra
5) Halquinol API Manufacturing Unit in Vatva, Gujarat
Focus on Quality and Regulatory Compliance
All of Stallen’s plants are certified and regularly audited by ISO, GMP, and FDA, along with approvals from international regulatory bodies, attestesting to their adherence to rigorous standards in manufacturing and product safety.
1) Feed Additives and Premix Factories in Maharashtra
Stallen South Asia Pvt. Ltd., based in Nandore, Maharashtra, India, specializes in manufacturing a wide range of feed additives and supplements. Their product portfolio includes antibacterial solutions, treatments targeting mycoplasmal infections, deworming agents, performance enhancers, anthelmintics, mineral supplements, toxin-binding formulations, antidiarrheals, growth promoters, anticoccidials, water sanitation products, fly control solutions, and disinfectants. These products are meticulously crafted and made available in various convenient forms such as tablets, boluses, powders, oral liquid solutions.
GMP Standard Manufacturing Layouts
1. Manufacturing Process: The factory has specialized equipment and facilities for the manufacturing process. This includes mixing and blending equipment for creating formulations, granulation machinery for solid products, liquid mixing and filling lines for liquids, and packaging lines for various forms of products.
2. Quality Assurance: Quality control measures are integral to the manufacturing process. Raw materials are tested for purity and quality before use. During production, in-process checks are conducted to ensure consistency and adherence to specifications. Finished products undergo rigorous quality testing for efficacy, safety, and compliance with regulatory standards.
3. Regulatory Compliance: The factory operates in compliance with regulatory requirements set by local and international regulatory bodies, with approvals from China, Iran, Australia and more. This includes adherence to Good Manufacturing Practices (GMP) and documentation of processes to ensure product quality and safety.
2) Formulation Unit in Palghar, Maharashtra, India.
It is a crucial facility for manufacturing pharmaceutical products that range between regular therapeutic drugs as well as beta-lactam formulations.
1. Facilities and Equipment: The formulation unit is equipped with state-of-the-art facilities and machinery required for the formulation and production of pharmaceutical products. This includes equipment for mixing, blending, granulation, drying, and packaging. The capacities are built for effervescent tablets, liquid form (oral and topical), oral powder, bolus and ointment.
2. Quality Control: Throughout the formulation process, rigorous quality control measures are implemented to ensure that the final product meets regulatory standards and specifications. This includes testing the raw materials, in-process samples, and the finished product for purity, potency, stability, and safety.
3. Regulatory Compliance: The formulation unit operates in compliance with regulatory requirements set by authorities such as the Food and Drug Administration (FDA) in India. This includes adherence to Good Manufacturing Practices (GMP), documentation of processes, and regular inspections to ensure quality and safety standards are maintained.
3) “Stallen Unveils Cutting-Edge API Facility for Halquinol Production!”
To maintain its commitment to quality, affordability, and timely delivery, Stallen has commenced the production of Halquinol, a non-antibiotic growth promoter classified under hydroxy-quinolines. This compound comprises 5-chloro-8-hydroxyquinoline, 5,7-Dichloro-8-hydroxyquinoline, and 7-Chloro-8-hydroxyquinoline, with the product Halquinol 98% manufactured in accordance with BP 80 (British Pharmacopeia 1980) specifications. Stallen offers Halquinol 98% as a chemical API for use in veterinary formulations and feed additives, alongside the commonly available 60% and 12% variants. With its adherence to BP specifications and increased monthly production capacity, Stallen is well-equipped to cater to global demand, holding valid registrations for Halquinol in over 15 countries.
Stallen’s strategic vision includes gradually introducing a range of APIs from its Vatva facility, aiming to reduce reliance on imported products from China in the animal health sector. The Vatva plant marks the fifth addition to Stallen’s manufacturing infrastructure, complementing its existing feed additive and veterinary formulation facilities in Palghar, Maharashtra, as well as a feed premix and additive manufacturing unit in Canada. This strategic expansion underscores Stallen’s commitment to self-sufficiency and quality assurance in delivering essential solutions for animal health and nutrition.
Stallen Cutting-Edge API Facility for Halquinol Production!
